NVS
Novartis AG ADR
Chart
Technical data
$156.11
0.71%
$3.11
76
$154.48 (+1.1%)
$151.84 (+2.8%)
$145.71 (+7.1%)
$151.08 (+3.3%)
$170.46 (-8.4%)
$112.34 (+39.0%)
1.88M
1.17
2026-07-27
21
Basing
500
3.36%
1.99%
2.00%
0.89
41
99%
605
1254
2026-07-29
$153.79
41
2026-07-27
Upcoming confluences
| Date | Price | Score | Price levels | Time levels |
|---|---|---|---|---|
| 2026-07-29 | $153.79 | 8 | 20 | 12 |
| 2026-07-29 | $165.73 | 4 | 12 | 12 |
| 2026-07-29 | $147.97 | 4 | 12 | 12 |
| 2026-08-06 | $153.79 | 5 | 20 | 7 |
| 2026-08-13 | $153.79 | 4 | 20 | 5 |
| 2026-09-04 | $153.79 | 4 | 20 | 4 |
| 2026-09-21 | $153.79 | 4 | 20 | 6 |
Fundamental data
Novartis AG ADR
Healthcare
Drug Manufacturers - General
$284.16B
$265.45M
1.83B
—
0.29%
3.07
12.56%
27.57%
—
76
—
Fundamental analysis
No analysis yet. This will pull the latest 10-K, 10-Q, and DEF 14A from SEC EDGAR, ingest the company's XBRL financial facts, compute Beneish / Altman / Piotroski / Sloan / Penman–Nissim, run Greenwald EPV + Mauboussin reverse-DCF, and synthesise a Columbia-style moat, earnings quality, and capital allocation review. Cached for 90 days.
News (9)
| Published (UTC) | Session | Sentiment | Category | Move % | Headline |
|---|---|---|---|---|---|
| 2026-07-21 15:00 | Regular |
Bullish |
EarningsBeat |
2.88% | Novartis AG (NVS) Q2 2026 Earnings Call Highlights: Strong Growth in Key Brands Amidst ... |
| 2026-07-21 13:12 | PreMarket |
Bullish |
EarningsBeat |
2.88% | Novartis Profit Beats Estimates as Entresto Sales Plunge 50% |
| 2026-07-21 09:24 | PreMarket |
Bullish |
EarningsBeat |
2.88% | Novartis Q2 2026 earnings beat as cancer, MS drugs drive growth |
| 2026-07-21 08:15 | PreMarket |
Bullish |
EarningsBeat |
2.88% | Novartis Earnings Beat, Cash Flow Weakens |
| 2026-07-21 07:31 | AfterHours |
Bullish |
EarningsBeat |
2.88% | Novartis Q2 profits recover as revenue mantle passes to newer medicines |
| 2026-07-17 07:36 | AfterHours |
Bullish |
FdaApproval |
0.67% | FDA grants traditional approval to Novartis' Fabhalta for IgAN |
| 2026-07-14 06:14 | AfterHours |
Bullish |
PartnershipAnnounced |
-1.96% | Novartis and Chai Discovery collaborate on antibody identification |
| 2026-07-07 12:38 | PreMarket |
Neutral |
AcquirerAnnounced |
0.99% | Novartis Buys Myricx Bio in $1.5 Billion Deal |
| 2026-07-06 07:05 | AfterHours |
Neutral |
AcquirerAnnounced |
-2.76% | Novartis to acquire Myricx Bio in up to $1.5bn deal |
SEC Filings (0)
No SEC filings cached for CIK 1114448 yet — run a fundamental analysis to import the last 3 years.
Beneficial Ownership 5%+ (0)
No SC 13D / 13G filings parsed for this symbol in the last 2 years.
Institutional Holders (0)
CUSIP not yet known for NVS. Three population pathways: (1) the next fundamental analysis run extracts it from any SC 13D/G cover page filed against NVS (cover pages print the subject-company CUSIP near the top); (2) the daily Form13FIngestionJob auto-links from a 13F-HR holding whose IssuerName uniquely matches NVS's CompanyName; (3) manual SQL update on the Tickers row. Once linked, institutional holders appear below.
Current setups (0)
No open or triggered setups for NVS right now.